This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Diabetes Mellitus, Type 1
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of MDI or CSII. Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.

Provided treatments

  • Drug: Empagliflozin
  • Drug: Empagliflozin
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT02414958. The sponsor of the trial is Boehringer Ingelheim and it is looking for 730 volunteers for the current phase.
Official trial title:
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)